Lung transplant

Lung transplantation is offered when a chronic lung disease has progressed to the point that breathing is failing and life expectancy is short, but before the person has become too unwell to survive the operation. Finding that window is the whole art of referral, and referring late is a more common error than referring early.

The diseases that lead there are a small set. Chronic obstructive pulmonary disease and emphysema, including the inherited alpha-1 antitrypsin form. Idiopathic pulmonary fibrosis and the other interstitial lung diseases, which now account for the largest share in many countries. Cystic fibrosis and other causes of severe bronchiectasis. Pulmonary arterial hypertension, where the problem is the lung circulation rather than the airways.

What transplantation offers is a genuine restoration of breathing: people who were tethered to oxygen and unable to cross a room frequently return to walking, working and travelling. What it does not offer is a normal life expectancy. Lung transplant outcomes remain the least good of the solid organs, and being told that clearly at the start is part of consenting properly.

The reason is specific rather than mysterious. The transplanted lung is the only organ in continuous contact with the outside air, breathing in everything the environment carries, while its normal defences — the cough reflex, mucociliary clearance, lymphatic drainage — are all disrupted by the surgery. That drives both the higher infection rate and the chronic scarring process that eventually limits most grafts.

A lung transplant is therefore best understood as trading one serious illness for another that is usually more liveable. Most recipients say it was worth it. Nobody should be told it is a cure.

A single lung transplant replaces one lung and leaves the other in place. It uses one donor organ, so two recipients can benefit from one donor, and it is a smaller operation for the patient. It suits some people with fibrosis or emphysema, particularly older recipients, but leaves the native lung — and its disease — behind.

A double lung transplant, usually performed as two sequential single transplants through one incision, replaces both. It is necessary wherever infection is the problem, because leaving one chronically infected lung beside a newly transplanted one would seed it immediately: this makes it mandatory in cystic fibrosis and bronchiectasis. It is also standard for pulmonary hypertension and is now the more common operation overall, with better long-term function in most groups.

Heart-lung transplantation is reserved for people whose heart and lungs have both failed beyond repair, most often from congenital heart disease with Eisenmenger physiology. It is now uncommon, partly because many people once treated this way can be managed with a double lung transplant while their heart recovers.

Lobar transplantation covers two different things. Cadaveric lobar transplantation uses lobes cut down from a deceased donor whose lungs are too large for a small recipient. Living-donor lobar transplantation uses two healthy donors, each giving one lower lobe, and exists in only a few programmes worldwide.

Two technologies sit alongside these. Ex vivo lung perfusion assesses and reconditions donor lungs outside the body before a decision is made. Extracorporeal membrane oxygenation can support somebody whose lungs are failing while they wait, and is increasingly used to keep a candidate awake and mobile rather than sedated — which materially improves their chance of surviving the transplant.

Lung transplant eligibility turns on two judgements made together: that the lung disease will shorten life within a few years and cannot be treated any other way, and that everything else about the person can withstand the operation and the immunosuppression that follows.

The disease-specific triggers differ. In pulmonary fibrosis, referral is recommended at diagnosis of the progressive forms, because decline can be fast and unpredictable. In COPD, severe airflow obstruction with rising carbon dioxide, repeated exacerbations or pulmonary hypertension. In cystic fibrosis, falling lung function with frequent hospital admissions, worsening carbon dioxide levels, or massive haemoptysis. In pulmonary arterial hypertension, persistent right heart failure and poor functional class despite full drug therapy.

Assessment then examines everything else. The heart is studied, because right ventricular strain is common and severe coronary disease may need treating first. Kidney and liver function, bone density, nutrition, muscle mass and frailty are all measured. Body weight matters in both directions: severe underweight and severe obesity both worsen outcomes and are usually addressed before listing.

Infection is scrutinised particularly closely in lung candidates, because it is the risk that most often follows them across the operation. Airway colonisation with resistant organisms, non-tuberculous mycobacteria and certain fungi may complicate or prevent listing depending on the organism and the programme. Dental infection is treated first.

Some factors are usually absolute barriers: active cancer, uncontrolled infection elsewhere, severe disease in another organ that cannot be fixed or transplanted alongside, current smoking or active substance use, and an inability to participate in rehabilitation. Others are relative and negotiable — age, previous chest surgery, prior pleurodesis, mechanical ventilation — and are weighed by the individual programme.

Smoking deserves its own sentence. Every programme requires documented abstinence, usually with testing, and this is not a moral judgement: continued smoking after transplantation destroys the graft and wastes an organ somebody else would have lived with.

Donor lungs are assessed harder than most organs because they are so easily damaged. The retrieval team reviews the donor's smoking history, the reason for death, chest imaging, oxygenation on standard ventilator settings, bronchoscopy findings and infection screening, and often inspects the lungs directly before accepting.

Matching depends on blood group compatibility and on size. Size is judged by predicted total lung capacity calculated from height and sex rather than by weight, because lungs must fit the chest cavity they are going into. Oversized lungs cannot be closed in; undersized lungs leave space and function poorly. Tissue typing is not routinely used to select lungs, though antibody screening matters for sensitised recipients.

Cold ischaemic time is limited — a matter of hours — which restricts how far lungs can travel. Ex vivo perfusion extends the assessment window and allows marginal organs to be reconsidered rather than discarded, and it has increased the number of usable donors in the programmes that have it.

Height is the practical constraint most patients are surprised by. A very tall or very short person waits longer simply because fewer donors match their chest size, and this is one of the few places where cadaveric lobar reduction or, in a few programmes, living-donor lobar transplantation becomes relevant.

What a candidate can influence is narrow but real: staying as strong and as well-nourished as possible, completing pulmonary rehabilitation, treating dental and sinus infection, keeping vaccinations current, and remaining contactable and able to reach the centre quickly when the call comes.

Lung transplantation carries the highest complication burden of the common solid organ transplants, and being told so plainly is part of a proper consent conversation.

Early, the dominant risk is primary graft dysfunction: a form of severe lung injury appearing in the first three days, causing poor oxygenation and requiring prolonged ventilation or ECMO. Most cases resolve, but severe grades carry significant mortality and are associated with worse long-term outcomes.

The airway join is a vulnerability unique to this operation. The donor bronchus loses its own blood supply and depends on collateral flow until it heals, so it can narrow or, less often, break down. Narrowing is common enough that programmes watch for it, and it is usually treated at bronchoscopy with dilatation or a stent.

Infection is the persistent risk. The graft is ventilated with outside air, the cough reflex is blunted by denervation, and mucociliary clearance is impaired, all while the recipient is immunosuppressed. Bacterial pneumonia, cytomegalovirus, aspergillus and other fungi are all more common than after other transplants, and prophylaxis against them is a routine part of care.

Acute rejection is frequent in the first year, often without symptoms, which is why programmes use surveillance bronchoscopy with biopsies and ask recipients to measure their own lung function at home. A sustained fall in home spirometry is treated as rejection or infection until proven otherwise.

The defining long-term problem is chronic lung allograft dysfunction — an irreversible decline in graft function that eventually affects the majority of recipients. Its commonest form, bronchiolitis obliterans syndrome, scars the small airways; a restrictive form scars the lung tissue itself. Treatment can slow it but rarely reverses it, and it is the principal reason lung transplant survival lags behind that of other organs.

The familiar transplant complications apply as well: kidney damage from calcineurin inhibitors, diabetes, hypertension, osteoporosis, skin cancers and post-transplant lymphoproliferative disorder. Reflux is specifically important here, because acid reaching the graft is thought to contribute to chronic rejection, and some programmes treat it surgically.

Assessment is carried out over several weeks by a multidisciplinary team and covers the lungs, everything else, and the practical life around the operation.

The respiratory work-up establishes severity and confirms the diagnosis: full pulmonary function testing, arterial blood gases, a six-minute walk test, high-resolution CT, and often a right heart catheterisation because pulmonary hypertension changes both the risk and the choice of operation. Sputum is cultured to identify colonising organisms.

The general work-up looks for anything that would not survive immunosuppression: cardiac assessment, kidney and liver function, bone density, nutritional status, screening for infection including tuberculosis and hepatitis, dental review and age-appropriate cancer screening. Vaccinations are completed before listing, since live vaccines cannot be given afterwards.

Pulmonary rehabilitation is not preparation in the ordinary sense; it is part of the treatment. Candidates who arrive at surgery stronger recover faster and leave hospital sooner, and most programmes make participation a condition of listing. Nutritional support is used to correct both wasting and obesity.

Once listed, the person joins the lung transplant waiting list with a priority reflecting urgency and expected benefit. Waiting is unpredictable and depends heavily on blood group and chest size. During it, deterioration is managed actively, and some candidates are supported on ECMO as a bridge — ideally awake and still able to exercise.

Because lungs tolerate only a few hours outside the body, the call comes with little warning and the response has to be immediate: a packed bag, arranged transport, a phone that is always answered, and a clear plan for the family.

Lung transplant surgery begins only once the retrieval team has inspected the donor lungs and confirmed the offer. The recipient is anaesthetised and prepared in parallel, but nothing irreversible happens until that confirmation.

Access depends on the operation. A single lung transplant is usually performed through a thoracotomy on that side. A double lung transplant is most often done through bilateral anterolateral thoracotomies, sometimes joined across the breastbone as a clamshell incision, and occasionally through a sternotomy.

In a double transplant the lungs are replaced one at a time. The worse lung is removed first while the other continues to work, and each new lung is joined at three points: the bronchus, the pulmonary artery, and a cuff of the left atrium carrying the pulmonary veins. When the first is working, the second side is done the same way.

Whether the patient needs cardiopulmonary bypass or ECMO during surgery depends on whether they can tolerate one lung doing all the work. Many single transplants avoid it; pulmonary hypertension and many double transplants require it.

A single lung transplant may take four to six hours. A bilateral transplant commonly takes six to twelve, longer where the chest is scarred by previous surgery, pleurodesis or infection. Chest drains are placed on each operated side, and the patient goes to intensive care ventilated.

The new lungs are denervated below the join, and that has permanent consequences. The cough reflex from the graft is lost, so secretions are not cleared instinctively and recipients are taught to cough deliberately and regularly. It is a small-sounding detail that matters enormously to how well a graft does.

A lung transplant survival rate is best read as a curve with two distinct phases rather than as a single number. The first phase is the operation and the first months, where primary graft dysfunction and infection dominate. The second is the long slope afterwards, where chronic lung allograft dysfunction determines how long the graft lasts.

The international figures are published by the registry of the International Society for Heart and Lung Transplantation, broken down by era, diagnosis, and single versus bilateral transplant. Those breakdowns matter more than the headline: outcomes differ substantially between a young person with cystic fibrosis receiving two lungs and an older person with fibrosis receiving one.

Several things move an individual away from any average. The underlying diagnosis. Whether one lung or two were transplanted, with bilateral generally doing better in most groups. Condition at the time of surgery, including whether the person was ventilated or on ECMO. The presence of donor-specific antibodies. And, over the long run, whether reflux, infection and rejection episodes are treated promptly.

What the numbers do not convey is the change in daily life. Freedom from oxygen, the ability to walk upstairs, to work, to travel, to sleep lying flat — for most recipients these arrive within months and are the reason the operation is done at all.

The first days are spent in intensive care, ventilated at first while the new lungs settle. Weaning may take a day or considerably longer if graft dysfunction develops. Chest drains stay until air leaks stop and drainage falls.

Physiotherapy starts immediately and is central rather than supplementary. Because the graft cannot cough for itself, recipients are taught to cough on a schedule and to use breathing devices to keep the airways clear. Sitting, standing and walking begin as early as safety allows, often while still attached to drains.

The ward stay is spent stabilising immunosuppression, treating early infection, performing the first surveillance bronchoscopy, and teaching. That education is heavier than for other transplants: recognising drugs, understanding prophylaxis, learning to use a home spirometer and record readings daily, food safety, and knowing exactly which symptoms require a phone call.

Discharge in an uncomplicated course is commonly three to four weeks after surgery. Follow-up afterwards is intensive: weekly clinics at first, blood tests, drug levels, imaging, and bronchoscopy at intervals set by the programme.

Thoracotomy or clamshell incisions are painful, and pain control is a genuine part of recovery because somebody who cannot take a deep breath cannot clear their chest.

By three months most people are markedly more independent and lung function is approaching its plateau. Pulmonary rehabilitation continues throughout and is one of the strongest predictors of long-term function. Return to work is realistic for many by six months, depending on the job.

Home spirometry becomes a lifelong habit within the first weeks. A sustained drop of around ten per cent is the signal programmes ask recipients to report immediately, because early rejection and early infection are both far more treatable than late ones.

Life afterwards is organised around medication, monitoring and avoiding the things that damage a graft. It is more demanding than life after a kidney transplant, and most recipients settle into it within a few months.

Immunosuppression is lifelong, usually a calcineurin inhibitor with an antiproliferative agent and a steroid, adjusted by blood levels. Doses are typically higher than for other organs because the lung is more prone to rejection. Fixed timing matters, and levels are measured before the morning dose.

Interactions are a real hazard. Grapefruit and pomelo, several antifungals and antibiotics, some anti-epileptics and St John's wort all shift levels substantially. Antifungal drugs deserve particular attention here because lung recipients are prescribed them relatively often and they interact strongly.

Daily home spirometry is the single most useful habit a lung recipient has. It detects decline before symptoms, and it is what makes early treatment possible.

Infection prevention is practical rather than restrictive: hand hygiene, avoiding people with respiratory infections, food safety, keeping vaccines current excluding live vaccines, and avoiding gardening, compost, building dust and mouldy environments where aspergillus is concentrated. Masks in crowded indoor spaces are commonly advised, particularly early on.

Smoking is absolutely excluded, including passive exposure and vaping. Reflux is treated actively, sometimes surgically, because acid reaching the graft appears to contribute to chronic rejection.

Ordinary life does return. Work, exercise, travel and relationships are all realistic, with planning for medication supply and vaccination when travelling. The honest long-term picture is that most grafts eventually develop chronic dysfunction, and some recipients are assessed for a second transplant. Knowing that early is better than learning it late, and nothing available today protects a graft better than exact adherence, prompt reporting and consistent rehabilitation.

Figures shown here come from the price registry, each recorded with the source that verified it and the date it was checked. Where nothing appears, no current verified figure exists — more honest than an estimate written once and left to age.

Lung transplantation is performed only in accredited centres connected to a national donation and allocation system, because that is the only lawful way lungs reach an operating theatre. Hospitals listed on this platform are recorded from public references rather than marketing claims, and a hospital appearing here does not indicate that it can accept an international patient for transplantation.

For lung transplantation, "available in a country" describes surgical capability, not access. A country may run excellent programmes and still be entirely closed to a non-resident, because what governs access is the law on who may join a national waiting list.

Most systems allocate deceased-donor lungs to residents. Some permit non-resident listing under defined conditions, typically requiring residency status, insurance, or an inter-governmental arrangement, and often within a quota. Others prohibit it. Because these rules are set by health ministries rather than hospitals, a hospital's willingness to assess you tells you nothing about whether you could be listed.

Verify the position in writing with the relevant health ministry or national transplant authority, and treat an agency, intermediary or hospital sales department as unverified. An offer to arrange a listing for a fee is a criminal offence in most jurisdictions.

What can legitimately be sought abroad is different and real: a second opinion on whether transplantation is appropriate, specialist treatment of the underlying lung disease, or assessment at a centre with particular expertise in a rare diagnosis.